Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Immune Related Adverse Events: early-phase trial registry
1 of 2 indexed Immune Related Adverse Events trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Immune Related Adverse Events: 2 US clinical trials tracked, 1 recruiting.
Immune Related Adverse Events is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Columbia University, running 1 of these trials.
Enrollment posture brief
Registry condition immune-related-adverse-events
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Immune Related Adverse Events lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Immune Related Adverse Events on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Immune Related Adverse Events is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
Brigham and Women's Hospital
NCT06789601
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Columbia University
NCT04375228
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Immune Related Adverse Events records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Immune Related Adverse Events trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Immune Related Adverse Events page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Immune Related Adverse Events trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Columbia University sponsors the most Immune Related Adverse Events trials on record, review their full trial history before evaluating a specific study. See Columbia University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Immune Related Adverse Events condition card totals 2 registered trials; most-linked intervention Standard eligibility monitoring; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.